Premium
In vitro assessment of apheresis and pooled buffy coat platelet components suspended in plasma and SSP+ photochemically treated with amotosalen and UVA for pathogen inactivation (INTERCEPT Blood System™)
Author(s) -
Chavarin P.,
Cognasse F.,
Argaud C.,
Vidal M.,
De Putter C.,
Boussoulade F.,
Ripaud C.,
Acquart S.,
Lin L.,
Garraud O.
Publication year - 2011
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.2010.01389.x
Subject(s) - buffy coat , apheresis , platelet , plateletpheresis , whole blood , in vitro , blood component , platelet rich plasma , chemistry , medicine , immunology , andrology , biochemistry , intensive care medicine
Background and Objectives INTERCEPT Blood System™ is a pathogen inactivation system for blood components. The initial approval required a platelet component to be suspended in a combination of plasma and Platelet additive Solution/PAS‐III. Improved platelet storage has been reported with Mg++ and K+ supplementation (PAS‐IIIM). This study validated the use of INTERCEPT™/PAS‐IIIM for apheresis and pooled buffy‐coat platelet components. Materials and Methods The platelet dose and pH throughout 5 days of storage met the European and French requirements for quality standards. Results and Conclusion Additional metabolic and activation assessments of the treated platelets confirmed the previously reported superiority of PAS‐IIIM over PAS‐III, but extended it to the INTERCEPT™ process.